159 related articles for article (PubMed ID: 14714216)
1. Striatal dopaminergic system in dopa-responsive dystonia: a multi-tracer PET study shows increased D2 receptors.
Rinne JO; Iivanainen M; Metsähonkala L; Vainionpää L; Pääkkönen L; Någren K; Helenius H
J Neural Transm (Vienna); 2004 Jan; 111(1):59-67. PubMed ID: 14714216
[TBL] [Abstract][Full Text] [Related]
2. D2 receptor binding in dopa-responsive dystonia.
Künig G; Leenders KL; Antonini A; Vontobel P; Weindl A; Meinck HM
Ann Neurol; 1998 Nov; 44(5):758-62. PubMed ID: 9818931
[TBL] [Abstract][Full Text] [Related]
3. Striatal D2 receptors in symptomatic and asymptomatic carriers of dopa-responsive dystonia measured with [11C]-raclopride and positron-emission tomography.
Kishore A; Nygaard TG; de la Fuente-Fernandez R; Naini AB; Schulzer M; Mak E; Ruth TJ; Calne DB; Snow BJ; Stoessl AJ
Neurology; 1998 Apr; 50(4):1028-32. PubMed ID: 9566390
[TBL] [Abstract][Full Text] [Related]
4. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.
Antonini A; Schwarz J; Oertel WH; Pogarell O; Leenders KL
Mov Disord; 1997 Jan; 12(1):33-8. PubMed ID: 8990051
[TBL] [Abstract][Full Text] [Related]
5. Dopamine transporter imaging (123)I-FP-CIT (DaTSCAN) SPET in differential diagnosis of dopa-responsive dystonia and young-onset Parkinson's disease.
Brajkovic LD; Svetel MV; Kostic VS; Sobic-Saranovic DP; Pavlovic SV; Artiko VM; Obradovic VB
Hell J Nucl Med; 2012; 15(2):134-8. PubMed ID: 22833860
[TBL] [Abstract][Full Text] [Related]
6. VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET.
De La Fuente-Fernández R; Furtado S; Guttman M; Furukawa Y; Lee CS; Calne DB; Ruth TJ; Stoessl AJ
Synapse; 2003 Jul; 49(1):20-8. PubMed ID: 12710012
[TBL] [Abstract][Full Text] [Related]
7. Comparison of striatal 18F-dopa uptake in adult-onset dystonia-parkinsonism, Parkinson's disease, and dopa-responsive dystonia.
Turjanski N; Bhatia K; Burn DJ; Sawle GV; Marsden CD; Brooks DJ
Neurology; 1993 Aug; 43(8):1563-8. PubMed ID: 8351012
[TBL] [Abstract][Full Text] [Related]
8. [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors.
Antonini A; Schwarz J; Oertel WH; Beer HF; Madeja UD; Leenders KL
Neurology; 1994 Jul; 44(7):1325-9. PubMed ID: 8035939
[TBL] [Abstract][Full Text] [Related]
9. Positron emission tomographic studies of dopa-responsive dystonia and early-onset idiopathic parkinsonism.
Snow BJ; Nygaard TG; Takahashi H; Calne DB
Ann Neurol; 1993 Nov; 34(5):733-8. PubMed ID: 8239569
[TBL] [Abstract][Full Text] [Related]
10. Positron emission tomography shows reduced striatal dopamine D1 but not D2 receptors in juvenile neuronal ceroid lipofuscinosis.
Rinne JO; Ruottinen HM; Någren K; Aberg LE; Santavuori P
Neuropediatrics; 2002 Jun; 33(3):138-41. PubMed ID: 12200743
[TBL] [Abstract][Full Text] [Related]
11. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
Brooks DJ; Ibanez V; Sawle GV; Playford ED; Quinn N; Mathias CJ; Lees AJ; Marsden CD; Bannister R; Frackowiak RS
Ann Neurol; 1992 Feb; 31(2):184-92. PubMed ID: 1575457
[TBL] [Abstract][Full Text] [Related]
12. In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias.
Turjanski N; Lees AJ; Brooks DJ
Neurology; 1997 Sep; 49(3):717-23. PubMed ID: 9305330
[TBL] [Abstract][Full Text] [Related]
13. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.
Piggott MA; Marshall EF; Thomas N; Lloyd S; Court JA; Jaros E; Burn D; Johnson M; Perry RH; McKeith IG; Ballard C; Perry EK
Brain; 1999 Aug; 122 ( Pt 8)():1449-68. PubMed ID: 10430831
[TBL] [Abstract][Full Text] [Related]
14. [123I]beta-CIT single-photon emission tomography in DOPA-responsive dystonia.
Naumann M; Pirker W; Reiners K; Lange K; Becker G; Brücke T
Mov Disord; 1997 May; 12(3):448-51. PubMed ID: 9159746
[TBL] [Abstract][Full Text] [Related]
15. A new knock-in mouse model of l-DOPA-responsive dystonia.
Rose SJ; Yu XY; Heinzer AK; Harrast P; Fan X; Raike RS; Thompson VB; Pare JF; Weinshenker D; Smith Y; Jinnah HA; Hess EJ
Brain; 2015 Oct; 138(Pt 10):2987-3002. PubMed ID: 26220941
[TBL] [Abstract][Full Text] [Related]
16. PET shows that striatal dopamine D1 and D2 receptors are differentially affected in AD.
Kemppainen N; Ruottinen H; Nâgren K; Rinne JO
Neurology; 2000 Jul; 55(2):205-9. PubMed ID: 10908891
[TBL] [Abstract][Full Text] [Related]
17. Presynaptic and postsynaptic striatal dopaminergic function in neuroacanthocytosis: a positron emission tomographic study.
Brooks DJ; Ibanez V; Playford ED; Sawle GV; Leigh PN; Kocen RS; Harding AE; Marsden CD
Ann Neurol; 1991 Aug; 30(2):166-71. PubMed ID: 1897909
[TBL] [Abstract][Full Text] [Related]
18. Long-term treatment response and fluorodopa positron emission tomographic scanning of parkinsonism in a family with dopa-responsive dystonia.
Nygaard TG; Takahashi H; Heiman GA; Snow BJ; Fahn S; Calne DB
Ann Neurol; 1992 Nov; 32(5):603-8. PubMed ID: 1449240
[TBL] [Abstract][Full Text] [Related]
19. Clinical heterogeneity of dopa-responsive dystonia: PET observations.
Takahashi H; Snow BJ; Nygaard TG; Calne DB
Adv Neurol; 1993; 60():586-90. PubMed ID: 8420195
[TBL] [Abstract][Full Text] [Related]
20. Role of dopaminergic treatment in dopamine receptor down-regulation in advanced Parkinson disease: a positron emission tomographic study.
Thobois S; Vingerhoets F; Fraix V; Xie-Brustolin J; Mollion H; Costes N; Mertens P; Benabid AL; Pollak P; Broussolle E
Arch Neurol; 2004 Nov; 61(11):1705-9. PubMed ID: 15534182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
